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Clinicalmicrobiological case: refractory chest wall infection
following reconstructive surgery in a patient with relapsed
lung cancer
A. Safdar, M. Bains and B. Polsky
Please refer to the article on pages 563–564 of this issue to view
the questions to which these answers refer.
CLINICAL OUTCOME
Ten weeks following the start of empirical therapy for Myco-
bacterium tuberculosis (isoniazid 300 mg, rifampin 600 mg,
ethambutol 1200 mg and pyrizinamide 1500 mg daily), the
patient’s symptoms progressed. A second chest wall exploration,
including extensive debridement and removal of the infected
prolene mesh, was performed 12 weeks later. Fibroadipose
tissue, breast and skeletal muscle specimens revealed acute
and chronic (dimorphic) inflammation, with foreign body giant
cell reaction. Acid-fast bacilli and granuloma were conspicu-
ously absent, and the chest wound was left to heal by secondary
intention (Figure 2).
Three weeks after surgery, M. fortuitum and M. abscessus were
isolated from all surgical specimens. Treatment was changed to
oral ciprofloxacin (500 mg) and clarithromycin (500 mg) twice
daily and continued for 6 months. The chest wound healed
completely, and mastitis resolved (Figure 3). No recurrence was
reported on 18-month follow-up.
DIAGNOSIS
M. fortuitum and M. abscessus prosthetic device infection.
DISCUSSION
1. Infections due to the rapidly growing mycobacteria (RGM)
have emerged as an important cause of morbidity and mortality
for humans, and are often seen in patients following penetrating
trauma and reconstructive surgery [1–3].M.chelonae,M.fortuitum
Figure 2 The left anterio-lateral chest wall wound following surgical debri-
dement and prolene mesh removal.
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and M. abscessus are commonly isolated in this setting, and
human infections are sporadic [2,3]. Integument, muscles, bone
and joints are frequently involved. Pulmonary infections are
uncommon and clinically indistinguishable from other causes of
mycobacterial lung disease due to M. tuberculosis, M. avium and
M. kansasii [4].
2. Tissue contamination during surgical procedures or
implantation of an infected prosthetic device are considered
to be common mechanisms for postoperative wound and deep
tissue infections due to RGM. Infections following augmenta-
tion mammoplasty, reconstructive cosmetic surgery, and post-
thoracotomy sternal osteomyelitis, and late prosthetic joint
infections, are such examples [5–8]. We suspect that placement
of an infected prolene mesh was associated with this locally
progressive infection in our patient that presented as a refractory
early postsurgical wound infection.
3. Generally, infections due to M. chelonae, M. fortuitum and
M. abscessus are insidious, and often remain localized to the
initial site of infection. However, in patients with severe cellular
immune dysfunction, such as those with profound
CD3þCD4þ lymphocytopenia due to HIV infection or hema-
tologic malignancy, a more fulminant course may be expected,
and systemic dissemination is not uncommon [9].
4. Clinically, M. tuberculosis infection is indistinguishable from
infections due to RGM. In patients with skin and soft tissue
infections, a plethora of acid-fast bacilli arranged in clusters
among granulocytic intradermal microabscesses is highly sug-
gestive of a process due to M. fortuitum or M. chelonae [9–12].
Similarly, dimorphic inflammation (acute and chronic), granulo-
cytic microabscesses and occasional non-necrotizing granuloma
are rarely seen in patients with pulmonary tuberculosis [2,13].
5. The ability of these microorganisms to form biofilms on
semi-implantable and implantable foreign devices appears to
play a central role in promoting refractory disease, by allowing
them to escape host immune surveillance, and by leading to
suboptimal antimicrobial drug penetration [13]. The partial,
subtherapeutic exposure to antimicrobials may also lead to drug
resistance and treatment failure. It is critical to remove these
infected prosthetic devices, as antimicrobial therapy alone is
often inadequate in successfully eradicating infections.
6. Therapy with two or more antimycobacterial agents is
often recommended. Trimethoprim–sulfamethoxazole, doxy-
cycline, minocycline and amikacin show the highest in vitro
activity against M. fortuitum and M. chelonae [14]. Most RGM
show variable (in vitro) resistance to the conventional anti-M.
tuberculosis agents, such as isoniazid, rifampin, pyrazinamide, and
ethambutol [2]. Clinical experience with ciprofloxacin, imipe-
nem and clarithromycin is promising [15,16]. Our patient
responded favorably to a combination of ciprofloxacin and
clarithromycin therapy.
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